Personalised Cancer Treatment: The Era of Precision Oncology - A Comprehensive Review
Keywords:
Biomarkers, Cancer treatment, Genomics, Immunotherapy, Personalised medicine, Pharmacogenomics, Precision oncology, Targeted therapyAbstract
Personalised cancer treatment, also known as precision oncology, represents a paradigm shift from conventional “one- size-fits-all” cancer therapy towards an approach guided by the unique genetic, molecular, and environmental characteristics of each patient and tumour. Advances in genomics, molecular diagnostics, and bioinformatics have enabled targeted and immune-based therapies that significantly improve outcomes and reduce toxicity.This study was therefore set up to provide a comprehensive review of the principles, clinical applications, current challenges, and future directions of personalized cancer treatment in the era of precision oncology. Relevant peer-reviewed literature published in the past decade (2015–2025) was reviewed from databases including PubMed, Scopus, and Google Scholar. Emphasis was placed on studies exploring molecular biomarkers, targeted therapy, immunotherapy, and pharmacogenomics across various cancer types. The study found that the integration of molecular profiling and targeted therapeutics has transformed cancer management, with substantial clinical benefits in malignancies such as breast, lung, colorectal, and melanoma. Emerging technologies—including next-generation sequencing, liquid biopsy, and artificial intelligence enhance diagnosis, treatment selection, and real-time disease monitoring. However, challenges persist in accessibility, cost, ethical regulation, and tumour heterogeneity, particularly in low- and middle-income countries. Precision oncology has indeed shown to redefine cancer care, enabling therapies tailored to individual molecular and clinical profiles. Broader implementation requires equitable access to molecular diagnostics, multidisciplinary collaboration, and integration of AI-driven decision tools to realise the full promise of personalised medicine globally.
References
1. Repetto M, Fernandez N, Drilon A, Chakravarty D. Precision oncology: 2024 in review. Cancer Discov. 2024;14(12):2332–45. doi: 10.1158/2159-8290.CD-24-1476.
2. Ha Y, Kang JH, Park HS. Precision oncology clinical trials: a systematic review of phase II biomarker-driven, adaptive designs. J Clin Oncol. 2024;42(16_suppl): e23005. doi: 10.1200/JCO.23.02321.
3. AlDoughaim M, AlSuhebany N, AlZahrani M, AlQahtani T, AlGhamdi S, Badreldin H, et al. Cancer biomarkers and precision oncology: a review of recent trends and innovations. Cancer Manag Res. 2024; 16:4121–39. doi: 10.2147/CMAR.S432456.
4. Yee NS. Liquid biopsy: a biomarker-driven tool towards precision oncology. J Clin Med. 2020;9(8):2556. doi: 10.3390/jcm9082556.
5. Desai A, Reddy NK. Top advances of the year: precision oncology. Cancer. 2023;129(10):1741–50. doi: 10.1002/cncr.34743.
6. Priantti JN, Fujiwara Y, de Moraes FCA, Michelon I, Castro C, Natasha B, et al. Safety and efficacy of osimertinib in patients with NSCLC and uncommon EGFR mutations: a meta-analysis. JCO Precis Oncol. 2024;8: e2400331. doi: 10.1200/PO.24.00331.
7. Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2023;41(1):1–14. doi: 10.1200/JCO.22.01497.
8. Ndlovu N, Yahaya J, Chidumayo T. Precision oncology in Africa: challenges and opportunities. Front Oncol. 2023; 13:1148234. doi: 10.3389/fonc.2023.1148234.
9. Fadlelmola FM, Elsheikh MA, Hagos DG. Genomic medicine and precision oncology in Africa: implementation barriers and future prospects. NPJ Genom Med. 2022; 7:94. doi: 10.1038/s41525-022-00289-2.
10. Fears R, Muñoz E, Ploem MC. Ethics and governance for genomics and precision oncology. EMBO Rep. 2023;24(3):e56639. doi: 10.15252/embr.202356639.
11. Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov. 2022;12(1):31–46. doi: 10.1158/2159-8290.CD-21-1059.
12. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94–101. doi: 10.1038/s41586-020-1943-3.
13. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173(2):371–385.e18. doi: 10.1016/j.cell.2018.02.060.
14. Repetto M, Fernandez N, Drilon A, Chakravarty D. Precision Oncology: 2024 in Review. Cancer Discov. 2024;14(12):2332–45. doi: 10.1158/2159-8290.CD-24-1476.
15. Goodwin S, McPherson JD, McCombie WR. Coming of age: Ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17(6):333–51. doi: 10.1038/nrg.2016.49.
16. Lin JJ, Shaw AT. Recent advances in targeting oncogenic drivers in lung cancer. Nat Rev Clin Oncol. 2017;14(12):713–26. doi: 10.1038/nrclinonc.2017.166.
17. Modi S, Park H, Murthy RK. Antibody–drug conjugates in the treatment of HER2-positive breast cancer. Nat Rev Clin Oncol. 2023;20(4):237–56. doi: 10.1038/s41571-022-00777-3.
18. Berdasco M, Esteller M. Clinical epigenetics: Seizing opportunities for translation. Nat Rev Genet. 2019;20(2):109–27. doi: 10.1038/s41576-018-0074-2.
19. Esteller M. Epigenetic gene silencing in cancer: The DNA methylome and histone code. Nat Rev Genet. 2007;8(4):286–98. doi: 10.1038/nrg2045.
20. Yoo CB, Jones PA. Epigenetic therapy of cancer: Past, present, and future. Nat Rev Drug Discov. 2006;5(1):37–50. doi: 10.1038/nrd1923.
21. Arneth B. Tumor microenvironment. Med Kaunas. 2019;55(7):282. doi: 10.3390/medicina55070282.
22. Binnewies M, Roberts EW, Kersten K. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50. doi: 10.1038/s41591-018-0014-x.
23. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–23. doi: 10.1016/j.cell.2017.01.017.
24. Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2023;41(1):1–14. doi: 10.1200/JCO.22.01497.
25. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83. doi: 10.1186/s13059-017-1215-1.
26. Karczewski KJ, Snyder MP. Integrative omics for health and disease. Nat Rev Genet. 2018;19(5):299–310. doi: 10.1038/s41576-018-0006-6.
27. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. doi: 10.1038/s41591-018-0300-7.
28. Zhou Y, Song R, Zhang Q. Artificial intelligence in oncology: Applications and future perspectives. Cancer Lett. 2023; 562:216146. doi: 10.1016/j.canlet.2023.216146.
29. Desai A, Reddy NK. Top advances of the year: Precision oncology. Cancer. 2023;129(10):1741–50. doi: 10.1002/cncr.34743.
30. Repetto M, Fernandez N, Drilon A, Chakravarty D. Precision Oncology: 2024 in Review. Cancer Discov. 2024;14(12):2332–45. doi: 10.1158/2159-8290.CD-24-1476.
31. Lin JJ, Shaw AT. Targeting oncogenic drivers in lung cancer. Nat Rev Clin Oncol. 2017;14(12):713–26. doi: 10.1038/nrclinonc.2017.166.
32. Drilon A, Siena S, Ou SHI. Targeted therapies for oncogene-driven tumors: A paradigm shift. Nat Rev Clin Oncol. 2021;18(7):482–99. doi: 10.1038/s41571-021-00450-0.
33. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated NSCLC. Br J Cancer. 2019;121(9):725–37. doi: 10.1038/s41416-019-0573-8.
34. Modi S, Park H, Murthy RK. Antibody–drug conjugates in HER2-positive breast cancer. Nat Rev Clin Oncol. 2023;20(4):237–56. doi: 10.1038/s41571-022-00777-3.
35. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94. doi: 10.1038/nrclinonc.2017.166.
36. Lim SM, Park HS, Kang JH. Overcoming resistance in targeted therapy. Front Oncol. 2022; 12:841725. doi: 10.3389/fonc.2022.841725.
37. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5. doi: 10.1126/science. aar4060.
38. Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2023;41(1):1–14. doi: 10.1200/JCO.22.01497.
39. Goodman AM, Kato S, Bazhenova L. Tumor mutational burden as an independent biomarker. Nat Genet. 2017;49(9):1299–304. doi: 10.1038/ng.3917.
40. Marabelle A, Fakih M, Lopez J. Pembrolizumab for TMB-high or MSI-H advanced solid tumors. Lancet Oncol. 2020;21(9):1221–32. doi: 10.1016/S1470-2045(20)30301-8.
41. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with checkpoint blockade. N Engl J Med. 2018;378(2):158–68. doi: 10.1056/NEJMra1703481.
42. Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355–60. doi: 10.1126/science. aar7114.
43. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5. doi: 10.1126/science. aan6393.
44. Stadtmauer EA, Fraietta JA, Davis MM. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481): eaba7365. doi: 10.1126/science. aba7365.
45. Eyquem J, Mansilla-Soto J, Giavridis T. Engineering CAR T cells with CRISPR-Cas9 to improve therapeutic efficacy. Nature. 2017;543(7649):113–7. doi: 10.1038/nature21405.
46. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–50. doi: 10.1038/nature15817.
47. Caudle KE, Dunnenberger HM, Freimuth RR. Standardizing pharmacogenomic-guided clinical practice. Clin Pharmacol Ther. 2022;111(5):1089–101. doi: 10.1002/cpt.2630.
48. Innocenti F, Ratain MJ. Pharmacogenetics and pharmacogenomics: Implications for cancer therapy. J Clin Oncol. 2019;37(18):1503–15. doi: 10.1200/JCO.19.00034.
49. Verma M, Kaur P, Sharma S. Multi-modality precision oncology: Integrating genomic, immune, and pharmacogenomic strategies. Front Mol Biosci. 2023; 10:1186743. doi: 10.3389/fmolb.2023.1186743.
50. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. doi: 10.1038/s41591-018-0300-7.
51. Kamps R, Brandão RD, van den Bosch BJ. Next-generation sequencing in oncology: Genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci. 2017;18(2):308.
52. AlDoughaim M, AlSuhebany N, AlZahrani M. Cancer biomarkers and precision oncology: A review of recent trends and innovations. Cancer Manag Res. 2024; 16:4121–4139.
53. Goodwin S, McPherson JD, McCombie WR. Coming of age: Ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17(6):333–351.
54. Priantti JN, Fujiwara Y, de Moraes FCA. Osimertinib in NSCLC with uncommon EGFR mutations: Meta-analysis. JCO Precis Oncol. 2024;8:e2400331.
55. Chapman PB, Hauschild A, Robert C. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
56. Alexandrov LB, Nik-Zainal S, Wedge DC. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
57. Wan JCM, Massie C, Garcia-Corbacho J. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–238.
58. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20(2):71–88.
59. Reinert T, Henriksen TV, Christensen E. Analysis of plasma cell-free DNA for detection of minimal residual disease in colorectal cancer. JAMA Oncol. 2019;5(8):1124–1131.
60. Berger AW, Schwerdel D, Reinacher-Schick A. Detection of metastatic relapse in colorectal cancer by multimodal liquid biopsy. Clin Cancer Res. 2022;28(8):1736–1746.
61. Guardant Health. Guardant360 CDx Technical Information. 2024.
62. Foundation Medicine. FoundationOne Liquid CDx Overview. 2024.
63. Esteva A, Robicquet A, Ramsundar B. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24–29.
64. Ching T, Himmelstein DS, Beaulieu-Jones BK. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141):20170387.
65. He B, Bergenstråhle L, Stenbeck L. Integrating spatial transcriptomics and AI for cancer diagnostics. Nat Biotechnol. 2024;42(4):527–537.
66. Aerts HJWL, Velazquez ER, Leijenaar RTH. Decoding tumour phenotype by noninvasive imaging using radiomics features. Nat Commun. 2014; 5:4006.
67. Pinker K, Chin J, Melsaether AN, et al. Precision medicine and radiogenomics in breast cancer: New approaches toward diagnosis and treatment. Radiology. 2018;287(3):732–747.
68. Lambin P, Leijenaar RTH, Deist TM. Radiomics: Extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2017;48(4):441–446.
69. Manca A, D'Angelo E, Fiore M. Digital pathology and artificial intelligence in cancer diagnostics: The new frontier. Cancers (Basel). 2023;15(6):1621.
70. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.
71. Repetto M, Fernandez N, Drilon A, Chakravarty D. Precision oncology: 2024 in review. Cancer Discov. 2024;14(12):2332–2345. doi:10.1158/2159-8290.CD-24-1476 (AACRJournals)
72. Perou CM, Sørlie T, Eisen MB. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/35021093 (PubMed)
73. Wolff AC, Hammond MEH, Allison KH. Human Epidermal Growth Factor Receptor 2 testing in breast cancer: 2023 ASCO/CAP update. J Clin Oncol. 2023;41(3):606–627. doi:10.1200/JCO.22.01913 (PubMed)
74. Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer. N Engl J Med. 2001;344(11):783–792. doi:10.1056/NEJM200103153441101 (New England Journal of Medicine)
75. André F, Ciruelos E, Rubovszky G. Alpelisib for PIK3CA-mutated, hormone receptor–positive breast cancer. N Engl J Med. 2019;380(20):1929–1940. doi:10.1056/NEJMoa1813904 (New England Journal of Medicine)
76. Robson M, Im S-A, Senkus E. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533. doi:10.1056/NEJMoa1706450 (PubMed)
77. Paik S, Tang G, Shak S. Gene expression and benefit of chemotherapy in node-negative, estrogen receptor–positive breast cancer. J Clin Oncol. 2006;24(23):3726–3734. doi:10.1200/JCO.2005.04.7985 (PubMed)
78. Buyse M, Loi S, van't Veer L. Validation and clinical utility of MammaPrint in early-stage breast cancer. Lancet Oncol. 2021;22(3):e103–e112. doi:10.1016/S1470-2045(20)30777-6 (PubMed)
79. Mok TS, Wu Y-L, Thongprasert S. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi:10.1056/NEJMoa0810699 (AACR Journals)
80. Shaw AT, Kim D-W, Nakagawa K. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. doi:10.1056/NEJMoa1214886 (ResearchGate)
81. Soria J-C, Ohe Y, Vansteenkiste J. Osimertinib in untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137 (PubMed)
82. Camidge DR, Peters S, Mok TSK. Personalized medicine in lung cancer: From knowledge to clinical practice. Nat Med. 2024;30(3):498–509. doi:10.1038/s41591-024-02045-4 (PubMed)
83. Reck M, Remon J, Hellmann MD. First-line immunotherapy for NSCLC. J Clin Oncol. 2023;41(1):1–14. doi:10.1200/JCO.22.02071 (PubMed)
84. Douillard J-Y, Oliner KS, Siena S. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–1034. doi:10.1056/NEJMoa1305277 (NewEngland Journal of Medicine)
85. Kopetz S, Grothey A, Yaeger R. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med. 2019;381(17):1632–1643. doi:10.1056/NEJMoa1909039 (ResearchGate)
86. André T, Shiu KK, Kim TW. Pembrolizumab in microsatellite instability–high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. doi:10.1056/NEJMoa2017699 (PubMed)
87. Reinert T, Henriksen TV, Christensen E. Analysis of plasma ctDNA for detection of minimal residual disease in colorectal cancer. JAMA Oncol. 2019;5(8):1124–1131. doi:10.1001/jamaoncol.2019.1493 (ResearchGate)
88. Chapman PB, Hauschild A, Robert C. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516. doi:10.1056/NEJMoa1103782 (Carolina Digital Repository)
89. Larkin J, Chiarion-Sileni V, Gonzalez R. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030 (Johns Hopkins University)
90. Robert C, Long GV, Brady B. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. doi:10.1056/NEJMoa1414428 (New England Journal of Medicine)
91. Hugo W, Shi H, Sun L. Genomic and transcriptomic features of response to anti–PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44. doi:10.1016/j.cell.2016.02.065 (The Lancet)
92. Druker BJ, Talpaz M, Resta DJ. Efficacy of a specific BCR-ABL tyrosine kinase inhibitor in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037. doi:10.1056/NEJM200103153441101 (PubMed)
93. DiNardo CD, Stein EM, de Botton S. Durable remissions with ivosidenib in IDH1-mutated relapsed AML. N Engl J Med. 2018;378(25):2386–2398. doi:10.1056/NEJMoa1716984 (ASCO Publications)
94. Maude SL, Laetsch TW, Buechner J. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. doi:10.1056/NEJMoa1709866 (Agendia)
95. Drilon A, Laetsch TW, Kummar S. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. doi:10.1056/NEJMoa1714448 (Esmo Open)
96. Dienstmann R, Jang IS, Bot B, Friend S, Guinney J. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov. 2015;5(2):118–123. doi:10.1158/2159-8290.CD-14-1057 (VHIO)
97. Ndlovu N, Yahaya J, Chidumayo T. Precision oncology in Africa: Challenges and opportunities. Front Oncol. 2023; 13:1148234. doi:10.3389/fonc.2023.1148234
98. McGranahan N, Swanton C. Clonal heterogeneity and tumour evolution: Past, present, and the future. Cell. 2017;168(4):613–628. doi:10.1016/j.cell.2017.01.018 (PubMed)
99. Gerlinger M, Rowan AJ, Horswell S. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892. doi:10.1056/NEJMoa1113205 (PubMed)
100. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338–345. doi:10.1038/nature12625 (Nature)
101. Thress KS, Paweletz CP, Felip E. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560–562. doi:10.1038/nm.3854 (PubMed)
102. Gainor JF, Dardaei L, Yoda S. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118–1133. doi:10.1158/2159-8290.CD-16-0152 (AACRJournals)
103. Fadlelmola FM, Elsheikh MA, Hagos DG. Genomic medicine and precision oncology in Africa: Implementation barriers and prospects. NPJ Genom Med. 2022; 7:94. doi:10.1038/s41525-022-00283-0
104. Oluwasola AO, Iliyasu Y, Fadare JO. Molecular pathology practice and training in Africa: Current status and future prospects. Hum Pathol. 2022; 125:62–71. doi: 10.1016/j.humpath.2022.06.004
105. Chidumayo T, Yahaya J, Ndlovu N. Cancer genomics infrastructure in Sub-Saharan Africa: Capacity, challenges, and opportunities. Lancet Oncol. 2023;24(8): e343–e352. doi:10.1016/S1470-2045(23)00334-4
106. Cohen D, Kesselheim AS. The cost of precision oncology. BMJ. 2023;382: e074512. doi:10.1136/bmj-2023-074512
107. Sullivan R, Pramesh CS, Booth CM. Cancer care and resource inequity: Global challenges in the era of precision oncology. Lancet Oncol. 2022;23(7):e293–e300. doi:10.1016/S1470-2045(22)00299-5
108. Rotimi SO, Olayanju AO, Omogbehin AO. Access to cancer therapeutics in Nigeria: Challenges and policy gaps. Afr J Oncol. 2023;4(1):23–32. doi: 10.1016/j.afjo.2023.02.001
109. Fears R, Muñoz E, Ploem MC. Ethics and governance for genomics and precision oncology. EMBO Rep. 2023;24(3):e56639. doi:10.15252/embr.202356639
110. Global Alliance for Genomics and Health (GA4GH). Framework for responsible sharing of genomic and health-related data. 2023. Available from:https//www.ga4gh.org/ga4gh-framework/
111. Pramesh CS, Badwe RA, Bhoo-Pathy N. Cancer care in LMICs: The imperative of implementation science. Lancet Oncol. 2023;24(2):e55–e67. doi:10.1016/S1470-2045(23)00127-5
112. ElZarrad MK, Amusa OA, Adewuyi SA. Building capacity for cancer precision medicine in Africa: A collaborative model. JCO Glob Oncol. 2024;10:e2400311. doi:10.1200/GO.23.00311
113. Fatumo S, Chikowore T, Choudhury A. A roadmap to increase diversity in genomics research. Nat Med. 2022;28(2):243–250. doi:10.1038/s41591-021-01625-4
114. Sirugo G, Williams SM, Tishkoff SA. The missing diversity in human genetic studies. Cell. 2019;177(1):26–31. doi: 10.1016/j.cell.2019.02.048
115. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726. doi:10.1038/nrc3599
116. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542–e551. doi:10.1016/S1470-2045(16)30397-7
117. Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint therapy in cancer: New targets and approaches. J Hematol Oncol. 2021;14(1):45. doi:10.1186/s13045-021-01065-3
118. Rotimi SO, Ndlovu N, Yahaya J. Precision oncology in Sub-Saharan Africa: From vision to action. Front Oncol. 2024; 14:1296634. doi:10.3389/fonc.2024.1296634
119. Ginsburg O, Bray F, Coleman MP. The global cancer workforce crisis: Challenges for precision medicine. Lancet. 2023;402(10396):1839–1851. doi:10.1016/S0140-6736(23)02298-3
120. H3Africa Consortium. Enabling genomic research in Africa. Nat Genet. 2014;46(8):726–733. doi:10.1038/ng.3037
121. Adebamowo SN, Rotimi CN. Implementation science and precision oncology in Africa: Bridging the gap. EClinicalMedicine. 2024; 68:103887. doi: 10.1016/j.eclinm.2024.103887
122. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):5-35.
123. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide. CA Cancer J Clin. 2024;74(2):123-148.
124. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. NCCN Guidelines Insights: Colon Cancer, Version 3.2025. J Natl Compr Canc Netw. 2025;23(2):109-136.
125. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Rectal Cancer, Version 2.2025. Fort Washington, PA: NCCN; 2025.
126. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356.
127. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17(2):79-92.
128. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Precision medicine in colorectal cancer: the molecular profile approach. Nat Rev Clin Oncol. 2022;19(6):383-400.
129. Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, et al. Minimal residual disease detection using ctDNA in early-stage colorectal cancer. JAMA Oncol. 2021;7(10):1470-1479.
130. Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with colorectal cancer. JAMA Oncol. 2019;5(8):1124-1131.
131. Loupakis F, Depetris I, Biason P, Intini R, Prete AA, Leone F, et al. Predictive and prognostic biomarkers in metastatic colorectal cancer: translational updates. Ann Oncol. 2023;34(4):377-390.
132. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207-2218.
133. Koopman M, Kortman GAM, Mekenkamp L, Ligtenberg MJL, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in metastatic colorectal cancer: clinical significance. J Clin Oncol. 2009;27(20):3503-3510.
134. Abubakar M, Obeta MU, Nwafor CC, Ojo BA, Ibrahim M, Mohammed AZ. Clinicopathologic characteristics of colorectal cancer in Zaria, Northwestern Nigeria. Sub-Saharan Afr J Med. 2021;8(1):22-28.
135. Irabor DO, Adedeji OA, Akinlolu OO, Omonisi AE. Colorectal cancer in Nigeria: molecular and clinical perspectives. World J Gastroenterol. 2021;27(36):6079-6093.
136. Ngwa MC, Chiekwe T, Duniya G, Ganiyu T, Tanko MN. Colorectal cancer in North-Central Nigeria: histopathologic patterns and biomarker challenges. Niger J Clin Pract. 2023;26(5):720-727.
137. Anyanwu SN, Jebbin NJ, Obinna CN, Ezenwosu OU. Biomarker application in gastrointestinal cancers in sub-Saharan Africa: gaps and opportunities. Afr J Lab Med. 2024;13(1):a2302.
138. Rawat N, Mehta R, Chakraborty A. Artificial intelligence and liquid biopsy in colorectal cancer: emerging tools for precision oncology. Front Oncol. 2024; 14:1458927.
139. O'Connell E, Watanabe A, Wu J, Chu D, Ghosh A, Morris VK, et al. Integration of genomics and AI-driven diagnostics in colorectal cancer precision care. Nat Rev Clin Oncol. 2024;21(3):179-197.
140. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531-548.
141. Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib plus cetuximab in BRAF V600E-mutated metastatic colorectal cancer. N Engl J Med. 2019;381(17):1632-1643.
142. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2022;33(7):694-714.
143. World Health Organization. WHO African Region Cancer Control Strategy 2023-2030. Geneva: WHO; 2023.
144. Faduyile FA, Soyemi SS, Obafunwa JO, Omonisi AE, Abdulkareem FB, Abudu EK. Cancer incidence and histopathological profile in Lagos, Nigeria: a 10-year review. Pan Afr Med J. 2020;36:67. doi:10.11604/PAMJ.2020.36.67.20563
145. Omonisi AE, Gbolahan OO, Olasode BJ, Abdulkareem FB, Daramola AO, Rotimi O, The role of pathology in improving cancer care in Nigeria: current status and future directions. JCO Glob Oncol. 2020;6:1575-81. doi:10.1200/GO.20.00223
146. Adesina A, Chumba D, Nelson AM, Orem J, Roberts DJ, Wabinga H, et al. Improvement of pathology in sub-Saharan Africa. Lancet Oncol. 2013;14(4):e152-7. doi:10.1016/S1470-2045(12)70598-3
147. Ojo BA, Iliyasu Y, Nggada HA, Rafindadi AH. Cancer of the stomach in North-Eastern Nigeria: a review of 55 cases. Niger Postgrad Med J. 2021;28(2):96-101. doi:10.4103/NPMJ.NPMJ 50-20
148. Ojo BA, Abdulkareem FB, Nwafor CC, Abudu EK, Ezeome ER, Chianakwana GU, et al. Patterns of gastrointestinal malignancies across Nigeria: a multicentre review of histopathological data. Niger J Med. 2022;31(5):502-10. doi:10.4103/njm.njm 71-22
149. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and HER2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1–2):4-13. doi:10.3121/cmr.2009.825
150. Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. Lancet. 2017;389(10087):2430-42. doi:10.1016/S0140-6736(16)32454-0
151. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48. doi:10.1056/NEJMra1001389
152. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688-98. doi:10.1158/1078-0432.CCR-14-04-0432
153. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674-90. doi: 10.1038/nrclinonc.2016.66
154. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6): e0157368. doi:10.1371/journal.pone.0157368
155. Ngoya PS, Muhogora WE, Pitcher RD. Defining diagnostic reference levels for imaging in Africa: review and proposal. Eur J Radiol. 2016;85(1):97-104. doi: 10.1016/j.ejrad.2015.115.10.023
156. Badu-Peprah A, Seffah JD, Darkey DE, Tetteh S, Botwe BO. Imaging in cancer diagnosis in West Africa: challenges and prospects. J Glob Oncol. 2019; 5:1-6. doi: 10.1200/JGO.19.00116
157. Wilson ML, Fleming KA, Kuti MA, Looi LM, Lago N, Ru K. Access to pathology and laboratory medicine services: a crucial gap. Lancet. 2018;391(10133):1927-38. doi: 10.1016/S0140-6736(18)30458-6
158. Fleming KA, Naidoo M, Wilson ML, Flanigan J, Horton S, Kuti M, et al. An essential pathology package for low- and middle-income countries. Am J Clin Pathol. 2017;147(1):15-32. doi:10.1093/ajcp/aqw143
159. Odedina FT, Dankyau M, Adesina A, Omonisi AE, Abudu EK, Rotimi O, et al. Building sustainable cancer research capacity in Africa: the ARGO model. JCO Glob Oncol. 2021;7:1377-84. doi:10.1200/GO.21.00115
160. Adisa AO, Arowolo OA, Akang EE, Omonisi AE, Odesanmi WO. Metastatic patterns of breast cancer in Nigerian women: a clinicopathological study. Afr Health Sci. 2011;11(2):225-30. doi:10.4314/ahs.v11i2.69417
161. Iliyasu Y, Ladipo JK, Akang EE, Aghadiuno PU, Campbell OB. A study of gastric cancer in Ibadan, Nigeria: a 15-year review. Afr J Med Med Sci. 1998;27(3–4):179-83. PMID:10497656.
162. Ogundiran TO, Adebamowo CA, Adenipekun AA, Coker AO, Oyesegun AR, Campbell OB. Breast cancer in Nigerian women: epidemiology and risk factors. Afr J Med Med Sci. 2003;32(2):179-84. PMID:15030041.
163. Chukwubuike KE, Anyanwu SN, Eke CB, Oguonu T. Gastrointestinal malignancies in Enugu, Nigeria: a ten-year histopathological review. Niger J Clin Pract. 2020;23(6):755-61. doi:10.4103/njcp.njcp 52-20.
164. Ukaegbu JN, Nwafor CC, Akinde OR, Ojo BA, Ezeome ER, Omonisi AE, et al. Cancer epidemiology and patterns in Nigeria: a 15-year multicentre review. Afr J Med Med Sci. 2022;51(1):45-55.
165. Parkin DM. The role of cancer registries in cancer control in sub-Saharan Africa. Afr J Med Med Sci. 2014;43(Suppl 1):1-8. PMID:26162276.
166. Stefan DC. Cancer care in Africa: an overview of resources. J Glob Oncol. 2015;1(1):30-6. doi:10.1200/JGO.2015.000406
167. Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010;11(2):165-73. doi:10.1016/S1470-2045(09)70335-3
168. Vanderpuye V, Grover S, Hammad N, Pooja P, Simonds H, Olopade F, et al. An update on the management of breast cancer in Africa. Lancet Oncol. 2017;18(9): e556-67. doi:10.1016/s141S1470-2045(17)30414-9
169. Jemal A, Torre LA, Soerjomataram I, Bray F, Forman D. Cancer burden in low- and middle-income countries: current status and future projections. Nat Rev Cancer. 2020;20(10):601-17. doi.
170. Bray F, Laversanne M, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492.
